Abstract: A system includes a reservoir located in a vehicle. The reservoir is configured to store a substance for eliminating at least one of germs and odors from an interior of the vehicle. The system further includes a dispenser fluidly coupled to the reservoir. The dispenser is configured to dispense the substance into the interior of the vehicle. The system further includes a pump configured to pump the substance from the reservoir to the dispenser. The system further includes a controller configured to detect when an occupant of the vehicle exits the vehicle. In response to detecting the occupant of the vehicle exiting the vehicle, the controller is further configured to activate the pump to dispense the substance from the dispenser into the interior of the vehicle to eliminate at least one of the germs and the odors from the interior of the vehicle.

Abstract: The disclosure relates to an improved connection for an air supply duct in a pilot helmet that includes a male connector and a female connector; wherein the female connector may include a tubular body defining an internal channel of air conduction and comprising an end connection section of greater diameter with an outgoing annular lip which defines a flat internal surface cavity in which a minimum of two magnets housed in at least two diametrically opposed holes are configured to couple with each other.

Abstract: The present invention relates to methods, processes, and systems for monitoring security policy violations in a computer network. Details of such monitoring include creating a rule according to a security policy, determining if the rule is violated by a value of a variable, and recording security events and comparing the number of events to a threshold.

Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

Abstract: A cover assembly including: first, second, and third substantially rectangular panel sections in a parallel relationship and the second panel being interposed between the first and third panels. The foldable cover assembly also includes the first, second, and third panels being pivotally connected such that the panels can fold in relation to one another so as to form the cover assembly into a triangular configuration or the panels can fold open to bring the panels to have a common plane. The foldable cover assembly also includes a fastening device for temporarily holding the cover assembly in the triangular configuration. The foldable cover assembly also includes where at least one of the panels having established thereon a hazard sign for signaling distress in situations involving motor vehicle traffic; and where the hazard sign can be directed towards the surrounding environment when the cover assembly is in the triangular configuration.

Abstract: A perforating gun includes a carrier, an explosive charge positioned within the carrier, a detonator positioned within the carrier, and a switch positioned within the carrier. The detonator detonates the explosive charge when the detonator receives power. The switch actuates between at least a first position and a second position. The switch transmits power to the detonator when the switch is in the first position, and the switch transmits power to a pyrotechnic device when the switch is in the second position. The pyrotechnic device detonates or deflagrates when the pyrotechnic device receives power.

Abstract: The present invention relates to an immunogen-carrier, wherein the immunogen-carrier is preferably a virus-like particle (VLP) composed of a plurality of a modified PCV2 ORF2 protein. In particular, the present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a compliance marker for vaccines including a subunit antigen, and a DIVA (Differentiating Infected from Vaccinated Animals) system which makes it possible to differentiate between animals infected with a pathogen and animals treated with a subunit antigen derived from said pathogen.

Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.

Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.

Abstract: A perforating gun includes a carrier, an explosive charge positioned within the carrier, a detonator positioned within the carrier, and a switch positioned within the carrier. The detonator detonates the explosive charge when the detonator receives power. The switch actuates between at least a first position and a second position. The switch transmits power to the detonator when the switch is in the first position, and the switch transmits power to a pyrotechnic device when the switch is in the second position. The pyrotechnic device detonates or deflagrates when the pyrotechnic device receives power.

Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.

Abstract: A magnetic connecting device for closing an electrical circuit through the use of magnetic force and contact plates. The contact plates are configured and shaped in a manner which allows for swiveling without disconnecting.

Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

Abstract: A wellbore perforating device includes at least one perforating charge and an initiator. The initiator can include a ballistic train adapted to fire the at least one perforating charge. The ballistic train can include a detonator and a detonator cord. A ballistic interrupt shutter can be disposed between the detonator and the detonator cord. The ballistic interrupt shutter can prevent firing of the detonator cord.

Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.

Abstract: The invention relates to a novel pharmaceutical formulation comprising polymer nanoparticles of the biodegradable and biocompatible polymer poly(lactic-glycolic) acid (PLGA), loaded with the drug pentoxifylline, the method for the synthesis of the PLGA nanoparticles loaded with pentoxifylline, and to the use thereof in the effective treatment for the relief of chronic pain and for the prevention of chronic pain via the administration of a single dose.

Abstract: A storage bin for a vehicle includes a bottom wall, and a support wall extending vertically upward from the bottom wall. A reflective triangle is coupled to the support wall. The reflective triangle is moveable between a stored position adjacent the support wall, and a deployed position extending vertically upward from the support wall. The storage bin supports the reflective triangle, and positions the reflective triangle in an upright vertical position, a distance above the bottom wall, when the reflective triangle is disposed in the deployed position. The storage bin is removable from a vehicle to remotely position the reflective triangle relative to the vehicle.

Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.